TOGETHER WITH

Welcome back to The Drop In, DoubleBlind’s newsletter serving up news, culture, and independent journalism about psychedelics straight to your inbox.

Today’s lead story is about Oregon’s move to consolidate its medical cannabis and its psilocybin services program. It’s happening amid financial concerns and proposing to increase licensing fees for psilocybin service centers, manufacturers, and facilitators. You can an official comment from Oregon Health Authority to DoubleBlind and our analysis below.

If you keep scrolling you’ll find stories to read about the similarities between raves and ceremonies, the impact of psychedelics on authoritarian attitudes, what psychedelic integration actually is, and a lot more.

PS- Also, if you’re going to be in Portland this week, join us in the City of Roses on July 10 for a magical evening of virtuosic multidimensional music and a conversation on psychedelia with DB co-founder Shelby Hartman and journalist Caitlin Donohue at The Lantern. See you there? ☺️

Happy World Cup 🇺🇸🏆,
Mary Carreón
Editor-in-Chief

Together With MV. Health

Orgasms So Intense, You Lose All Sense of Time

What if your orgasms felt so transcendent that time seemed to stop? Not because you were transported anywhere, but because you became completely present.

That’s the real gift of intimacy, and Tenuto 2 makes it possible – for both of you.

This award-winning wearable vibrator provides both partners with pleasure so overwhelming that time becomes optional.

Most pleasure peaks fast and drops, but Tenuto 2 keeps building arousal for both of you with 4 powerful motors that send tantalizing sensations to the penis, perineum, vulva, and clitoris at once. With an adaptable hold, this penis constriction ring helps you last longer while making you harder. All hands-free.

The climax lasts longer. The glow lasts days.

You'll both surface breathless from the afterglow with that disorienting, "wait, how long were we...?" feeling.

(It's even clinically proven to double erection strength and improve performance. Because we all know transcendent experiences benefit from good vibrations.)

Oregon Is Merging Its Psilocybin and Medical Cannabis Programs

The two programs are expected to function as a consolidated section by September 1, 2026, a cost-cutting move that arrives alongside a proposed doubling of licensing fees.

Oregon’s psilocybin and medical cannabis programs are merging into a single regulatory section, the Oregon Health Authority (OHA) confirmed to DoubleBlind on July 3. The decision comes as both programs contend with budget shortfalls that have pushed the OHA to look for new opportunities to cut costs and increase revenue.

 "Both Oregon Psilocybin Services (OPS) and the Oregon Medical Marijuana Program (OMMP) are experiencing budget shortfalls," a spokesperson for OHA's Public Health Division tells DoubleBlind in an email. "After taking steps to reduce costs (e.g., not filling vacant positions, reducing non-personnel costs), the next step in our resource-limited environment is to look for other impactful ways to increase efficiency and cost-effectiveness. To that end, OPS and OMMP will come together to form one section, the Oregon Psilocybin and Medical Cannabis Section (PMCS)."

The consolidation, first reported by Psychedelic Alpha on X, will gradually roll out over the summer and is slated to have a September 1 completion date. Angie Allbee, the current OPS manager, will lead the new section, and Megan Lockwood, who manages OMMP, will now head the Health Licensing Office. “Angie and Megan will be working closely to ensure a supportive transition for staff with a focus on continuity and stability for partners," OHA’s spokesperson tells DoubleBlind.

This merger arrives as OPS faces other financial pressures. As of July 1, the OHA has proposed doubling the program’s licensing fees, according to the Portland Business Journal. The proposal would increase the annual fee for service centers, manufacturers, and testing labs from $10,000 to $20,000, and facilitator fees would rise from $2,000 to $4,000. It would go into effect January 1, 2027, if adopted.

When voters approved legally guided psilocybin sessions via Measure 109 in 2020, the program was built to sustain itself on licensing fees rather than tax dollars. It has not achieved that thus far.

Operators warn the licensing fee increases could break an already fragile business and burgeoning industry. "If you try to charge $20,000 (for a service center license, up from $10,000 per annum) next year, I'm gonna have to go to another state," one service center operator told Lucid News. “The way the law is written, long-term, is what is going to constrain my success as an entrepreneur.”

It’s not just business owners who would take on the burden of increased licensing fees. Patients hoping to undergo supported psilocybin use legally, either with a therapist or other type of facilitator, will also see a price hike for treatment. Currently, psilocybin sessions in Oregon cost roughly between $500 for guided microdose experiences and $3,500 for higher-dose guided sessions, according to prior reporting by DoubleBlind. If licensing fees increase, an already pricey experience will move further out of reach, pushing people to the underground market for both mushrooms and unlicensed guides. Most psilocybin use and sourcing already exists outside of the clinical, therapy context but it still comes with risks. Plus, patients being forced to turn to the underground because a legal framework has made a product or service too expensive is a public health risk. Not to mention it mirrors one of the main issues of the American health insurance system.

The OPS and OMMP’s consolidation and the OPS licensing fee increases fit into a broader, turbulent context for Oregon drug policy. In 2020, voters passed Measure 109 alongside Measure 110, the latter decriminalized personal possession of all drugs. But without addressing the housing issue, increasing drug and mental health treatment programs, and other support infrastructure to hold up such an experiment, public drug use surged and lawmakers repealed Measure 110’s decriminalization in 2024 through House Bill 4002. It reinstated criminal penalties for personal possession while leaving the psilocybin therapy program intact. In effect, the laws allow access for people who can pay and criminal exposure for everyone else.

Reform hasn't stalled entirely, however. On July 2, a group of Portland city councilors introduced legislation that would make low-level psychedelic offenses the city’s lowest enforcement priority and create an expert commission to guide future policy, according to KATU 2 ABC News. However, psilocybin use and possession would remain illegal outside of licensed service centers in the state, and remain fully illegal under federal law.

& More Must-Reads

  • Weeping under the lasers? A new survey says the dance floor might be doing the same trauma work as a candlelit ceremony. Read more here.

  • Everyone jokes about giving Trump ayahuasca, but researchers say psychedelics don't rewrite politics, and might even backfire. Read more here.

  • No tree would consent to conscious capitalism — and neither should we, argues Alnoor Ladha. Read more here.

  • Just like cannabis, magic mushrooms may work best in full spectrum: new research finds synthetic psilocybin alone can't match the whole plant. Read more here.

  • Psychedelic integration is how you make sense of a trip after the visuals fade — and increasingly, it's becoming its own kind of therapy. Read more here.

DoubleBlind Digs

  • PSYCHEDELICS & SYSTEMS CHANGE: Most psychedelic conversations stop at personal healing, but DoubleBlind's Psychedelics and Systems Change Summit asks a bigger question: can these medicines help us heal our communities, our systems, and the planet we share? Join us on Sunday, July 26, for a free day of virtual talks, live Q&A, and movement with leading voices in the space. Can't make it live? Every registrant gets the full recording. Learn more here.

  • IN PORTLAND THIS WEEK?: On July 10, DoubleBlind teams up with multi-instrumentalists OHMA for Listening Beyond, a one-night-only evening of transcendent live music and psychedelic conversation at The Lantern, Portland's beautiful new space for grief and healing. DB co-founder Shelby Hartman and journalist Caitlin Donohue will catch you up on the latest in psychedelia, and admission is pay-what-you-can, so come be in community with us. Learn more here.

  • CACTI GRAFTING: This Sunday, July 12, the historic Shulgin Farm hosts a hands-on cacti grafting and plant alkaloid extraction workshop with Dr. Paul Daley and Bo Xu, and every attendee goes home with a grafted Trichocereus cutting to nurture. Learn more here.

  • WANT TO CONTRIBUTE TO A STORY? A journalist is working on a feature about 5-MeO-DMT and ibogaine for DoubleBlind. If a facilitator has ever administered 5-MeO to you post ibogaine treatment, we want to hear from you. Take this survey here.

  • BECOMING A KETAMINE THERAPIST: Enrollment is open for Alchemy's online 7-week Ketamine-Assisted Psychotherapy training, which clinicians can attend live or watch at their own pace, with all proceeds supporting our nonprofit mission of equitable psychedelic therapy. Learn more here.

Together With MV. Health

Nirvana Awaits With This Multi-Shape Vibrator

Nirvana awaits with this multi-shape vibrator that hits all the right spots. It’s called Crescendo 2, and it’s designed to be fully bendable to reach – and arouse – all your erogenous zones.

6 powerful motors stimulate everywhere it touches. Reignite the fire of your most electrifying encounters with sensations that intensify arousal.

It’s so sublime, even doctors recommend it for boosting arousal and supporting natural lubrication. FDA-registered, award-winning, FSA/HSA eligible – what more could you ask for?

Oh, it’s also 50% off during their sitewide sale.

Around the Web

  • A new review argues that psychedelics and anesthetics like ketamine and nitrous oxide may reshape consciousness through strikingly similar brain-network patterns — and that anesthesiologists could become key players in psychedelic science. Read more.

  • For the first time in U.S. history, an FDA-approved psychedelic therapy could be just months away, as Compass Pathways' synthetic psilocybin heads toward a late-2026 decision that may reshape care for millions with treatment-resistant depression. Read more.

  • Psychedelic Science 2027 asks the field to close the gap between what psychedelics promise and what practitioners are actually building — and MAPS is now taking speaker submissions through September 18. Read more.

  • One dose of the chemical in magic mushrooms made rats care less about big rewards, and scientists think the reason why could help explain how psychedelics might treat addiction. Read more.

💌 If you loved this email, forward it to a psychonaut in your life.

Reply

Avatar

or to participate

Keep Reading